NewsRelease

NatureProtocols Article Cites HemogloBind^TMin Drug Target Identification Methods for Malaria-parasite InfectedErythrocytes

MONMOUTHJUNCTION, NJ, April 30, 2020 -- Biotech Support Group reports on aresearch article published in Nature Protocols, describing thesimplicity and efficiency of their hemoglobin depletion technology tosurvey the red cell proteome, to identify drug-target interactions inMalaria-parasite infected erythrocytes.

Thecitation is:

Dziekan,Jerzy Michal, et al. "Cellularthermal shift assay for the identification of drug–targetinteractions in the Plasmodium falciparum proteome."Nature Protocols (2020): 1-41.

Theauthors describe how little is known about the cellular targets andthe mode of action of the vast majority of antimalarial drugs. Thecellular thermal shift assay (CETSA) protocol presents acomprehensive strategy for the identification of drug targets. CETSAenables proteome-wide target screening for unmodified antimalarialcompounds with undetermined mechanisms of action, providingquantitative evidence about direct drug–proteininteractions. The experimental workflow involves treatment of P.falciparum–infectederythrocytes with a compound of interest, heat exposure to denatureproteins, soluble protein isolation, enzymatic digestion, peptidelabeling with tandem mass tags, offline fractionation, and liquidchromatography–tandemmass spectrometry(LC-MS)analysis. Theprotocols present workflows for parasitized cell enrichment andhemoglobin depletion strategies for both lysate and intact-cellsample preparation, that are compatible with the CETSA assay andprovide satisfactory coverage of both parasite and RBC proteomes fromthe digested peptide analyses.

Thearticle states “The intact-cell CETSA protocol features aHemogloBind- based sample processing step, which provides arelatively fast, reliable and inexpensive method to deplete >90%of hemoglobin from processed intact-cell samples. As a result, itleads to a 40-50% increase in the number of peptide spectrum matches(PSMs) for P.falciparumand non-hemoglobin human proteins.”. The article concludes withmethodologicaloptimizations necessary for the analysis of this intracellularparasite, including hemoglobin depletion strategies to overcome highhemoglobin abundance in the host red blood cells.

“Iam very pleased to see that our product - HemogloBind^TMwas an enabling technology in this drug target identificationworkflow. While the article focused on use for malaria drugs, thediscussion describes how the workflow can be generally applied forinvestigating red cell susceptibility to many stressors at theproteome level. For COVID-19 research, this could include the reducedcapacity for red cells to exchange oxygen or the various stressorsimposed by the inflammatory response to the virus. Through theadoption of these methods, we hope this will lead to new drugs formany diseases”, states Swapan Roy, Ph.D., President and Founder ofBiotech Support Group.

Formore information on HemogloBind™, visit:

https://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

Formore information on all of our Hemoglobin removal products,visit:
https://www.biotechsupportgroup.com/Articles.asp?ID=452

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, and HemogloBind™ and HemoVoid™ for hemoglobinremoval. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, go tohttp://www.biotechsupportgroup.com

ForBusiness Development, Contact:
MatthewKuruc 732-274-2866, [email protected]